Janssen PMP (a division of Janssen Pharmaceutica) and Symphony have been working together to introduce a masterbatch for plastic products at the manufacturing stage.
The aim is to control bacteria such as E.coli, Salmonella, Listeria, Pseudomonas, and Aspergillus Niger; and algae and fungi such as M. Piriformis and P. Roqueforti.
It will be sold by Symphony and co-branded under the d2p brand name with commercial sales volumes for food-contact applications expected to come in 2014/15.
Michael Laurier, chief executive of Symphony, said: "We are already negotiating with large global users after positive laboratory tests and manufacturing trials with them, and await regulatory approval which we anticipate will be granted during 2014.”